Abstract
<p>Supplementary Figure 2: Heterozygous Pik3caH1047R oncogenic mutation causes invasive prostate cancer in mice that is phenotypically distinct to Pten-null prostate cancer. (A) Sequencing cDNA isolated from PBiCre+/-;Pik3ca+/HR prostate tissue confirmed heterozygosity at known silent base changes within mutant exon 20 adjacent to exon 19, indicating recombination has occurred. (B) allele-specific PCR of cDNA isolated from PBiCre+/- prostate tissue expressing either Pik3ca+/+ (Wt) or Pik3ca+/HR alleles (as previously described (13)) revealed the presence of the mutant exon 20 in PBiCre+/-;Pik3ca+/HR prostate cDNA, but not in PBiCre+/-;Wt prostate cDNA. (C) Representative H&E images of PBiCre+/-; Wt, Pik3ca+/HR and Ptenfl/fl ventral and anterior prostate epithelium at 400 d (scale bar: 100 um). Phenotype incidence plots for PBiCre+/-; Wt, Pik3ca+/HR and Ptenfl/fl ventral (D) and anterior (E) prostate lobes. VP = Ventral prostate, AP = anterior prostate, PIN = prostate intraepithelial neoplasia. (F) IHC to detect SMA in Wt, Pik3ca+/HR and Ptenfl/fl mice at 400 d (scale bar: 50 um). (G) Quantitation of PCNA-positive nuclei in PBiCre+/-; Pik3ca+/HR and Ptenfl/fl prostate hyperplastic lesions. *P <0.001, one-way ANOVA with Tukey's multiple comparison test, n = 3. Error bars: SEM.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
